Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × acalabrutinib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 30 Other hematologic neoplasm 19 Plasma cell 3 Gastrointestinal 2 Thoracic 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Classical hematology 1 CNS 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

Prednisone 120 Docetaxel 115 enzalutamide 96 pembrolizumab 94 Sunitinib 86 Leuprolide 83 Abiraterone Acetate 83 Gemcitabine 75 Nivolumab 74 bicalutamide 54 Radiotherapy 54 Bevacizumab 54 Goserelin 53 Cisplatin 52 Everolimus 49 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45 Magnetic Resonance Spectroscopy 45 Sorafenib 40 Carboplatin 39 Paclitaxel 36 atezolizumab 34 Radiosurgery 34 pazopanib 32 Ipilimumab 32 cabozantinib 30 abiraterone 29 Cyclophosphamide 29 Axitinib 29 avelumab 27 Radiation 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351739 2019-09-10

KEYNOTE143

Acerta Pharma BV

Phase 2 Completed

78 enrolled 10 charts

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡